Valneva SE (NASDAQ: VALN)

Valneva SE, a prominent player in the development of prophylactic vaccines for infectious diseases, is a public company listed on the Nasdaq Global Select Market and Euronext Paris. The company was established in 2013 through the merger of Intercell, an Austrian vaccine biotech company, and Vivalis, a French biotech company. Valneva's primary business activities revolve around the development, manufacturing, and commercialization of vaccines for infectious diseases.

The company's vaccine development efforts are concentrated on several candidates, including VLA1553, a single-dose, live-attenuated vaccine candidate against the chikungunya virus, VLA15, a vaccine candidate targeting Borrelia, the bacterium responsible for Lyme disease, and VLA1601, a highly purified inactivated, adjuvanted vaccine candidate against the Zika virus.

Valneva's revenue is primarily generated through the sale of its proprietary travel vaccines. These include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine, DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and ETEC, and IXCHIQ, a single-dose, live-attenuated vaccine indicated for the prevention of disease caused by chikungunya virus.

Valneva's competitive advantages stem from its strong track record of advancing vaccines from early research and development to approvals, its expertise in vaccine development and manufacturing, and its ability to leverage strategic partnerships to maximize the potential of its clinical and commercial portfolios. The company competes with other specialty vaccine companies such as Novartis and GlaxoSmithKline.

Valneva's customers include government agencies, healthcare providers, and pharmaceutical companies. The company's products are used to prevent infectious diseases, including Japanese encephalitis, cholera, and chikungunya.

One of Valneva's notable vaccine candidates is VLA1553, also known as IXCHIQ. This live-attenuated chikungunya vaccine is based on the East, Central, and Southern African (ECSA) strain, which has spread across the Indian Ocean. IXCHIQ is designed to protect against other strains as well, including the Asian lineage rapidly spreading across the Americas. Given its live-attenuated nature, IXCHIQ may confer life-long immunity.

The Phase 1 clinical trial of VLA1553 involved 120 adults and three doses of VLA1553. The primary endpoint was the evaluation of safety measures, including frequency and severity of injection site and systemic reactions. Chikungunya virus neutralizing antibodies were observed in 100% of patients for 12 months at all three doses evaluated.

The Phase 3 clinical trial, VLA1553-301, met its primary endpoint, inducing protective CHIKV neutralizing antibody titers in 98.9% of participants 28 days after receiving a single shot. The seroconversion rate result of 98.9% exceeded the 70% threshold agreed with the FDA.

IXCHIQ was also highly immunogenic in elderly study participants (65 years of age or older), who achieved equally high seroconversion rates and neutralizing antibody titers over time as younger adults. The final pivotal Phase 3 data were published in The Lancet in June 2023.

Another vaccine candidate in Valneva's pipeline is VLA15, a recombinant protein vaccine candidate targeting six serotypes of Borrelia, representing the most common serotypes found in North America and Europe. The vaccine is designed to generate antibodies that target the OspA protein on the surface of Borrelia, killing the bacteria before it can be transmitted from the infected tick to the human host.

The Phase 1 clinical trial of VLA15 involved 179 healthy adults with three doses of VLA15. The trial evaluated safety measures and immune responses. The results demonstrated a favorable safety profile and robust immune responses.

Valneva's strategy is focused on becoming an industry leader in the development of prophylactic vaccines, with a goal of developing vaccines that are first-, best-, or only-in-class. The company is pursuing this goal through a combination of internal research and development, strategic partnerships, and opportunistic acquisitions.